Intravenous thrombolysis for acute ischemic stroke in Greece: the Safe Implementation of Thrombolysis in Stroke registry 15-year experience by Tsivgoulis, Georgios et al.
Henry Ford Health System 
Henry Ford Health System Scholarly Commons 
Neurology Articles Neurology 
1-1-2018 
Intravenous thrombolysis for acute ischemic stroke in Greece: the 
Safe Implementation of Thrombolysis in Stroke registry 15-year 
experience. 
Georgios Tsivgoulis 
Odysseas Kargiotis 
Jobst Rudolf 
Apostolos Komnos 
Antonios Tavernarakis 
See next page for additional authors 
Follow this and additional works at: https://scholarlycommons.henryford.com/neurology_articles 
Recommended Citation 
Tsivgoulis G, Kargiotis O, Rudolf J, Komnos A, Tavernarakis A, Karapanayiotides T, Ellul J, Katsanos AH, 
Giannopoulos S, Gryllia M, Safouris A, Papamichalis P, Vadikolias K, Mitsias P, and Hadjigeorgiou G. 
Intravenous thrombolysis for acute ischemic stroke in greece: The safe implementation of thrombolysis in 
stroke registry 15-year experience. Ther Adv Neurol Disord 2018; 11:1756286418783578. 
This Article is brought to you for free and open access by the Neurology at Henry Ford Health System Scholarly 
Commons. It has been accepted for inclusion in Neurology Articles by an authorized administrator of Henry Ford 
Health System Scholarly Commons. 
Authors 
Georgios Tsivgoulis, Odysseas Kargiotis, Jobst Rudolf, Apostolos Komnos, Antonios Tavernarakis, 
Theodoros Karapanayiotides, John Ellul, Aristeidis H. Katsanos, Sotirios Giannopoulos, Maria Gryllia, 
Apostolos Safouris, Panagiotis Papamichalis, Konstantinos Vadikolias, Panayiotis Mitsias, and Georgios 
Hadjigeorgiou 
This article is available at Henry Ford Health System Scholarly Commons: https://scholarlycommons.henryford.com/
neurology_articles/113 
https://doi.org/10.1177/1756286418783578 
https://doi.org/10.1177/1756286418783578
Therapeutic Advances in Neurological Disorders
journals.sagepub.com/home/tan 1
Ther Adv Neurol Disord
2018, Vol. 11: 1–10
DOI: 10.1177/ 
1756286418783578
© The Author(s), 2018.  
Reprints and permissions:  
http://www.sagepub.co.uk/
journalsPermissions.nav
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License  
(http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission 
provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction
In the absence of specific contraindications, intra-
venous thrombolysis (IVT) remains the only 
approved systemic reperfusion treatment for acute 
ischemic stroke (AIS).1–3 The Safe Implementation 
of Thrombolysis in Stroke (SITS), the SITS 
Monitoring Study (SITS-MOST) and the SITS 
International Stroke Thrombolysis Register 
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Abstract
Background: Intravenous thrombolysis (IVT) remains the only approved systemic reperfusion 
treatment for acute ischemic stroke (AIS), however there are scarce data regarding outcomes 
and complications of IVT in Greece. We evaluated safety and efficacy outcomes of IVT for AIS 
in Greece using the Safe Implementation of Thrombolysis in Stroke: International Stroke 
Thrombolysis Register (SITS-ISTR) dataset.
Methods: All AIS patients treated with IVT in Greece between December 2002 and July 2017 
and recorded in the SITS-ISTR were evaluated. Demographics, risk factors, baseline stroke 
severity [defined using National Institutes of Health Stroke Scale (NIHSS)], and onset-to-
treatment time (OTT) were recorded. Safety outcomes included symptomatic intracranial 
hemorrhage (sICH) and 3-month mortality rates. The efficacy outcomes evaluated a 
reduction in baseline NIHSS score at 2 and 24 h following IVT onset, 3-month favorable 
functional outcome [FFO; modified Rankin scale (mRS) scores of 0–1] and 3-month functional 
independence (FI; mRS-scores of 0–2). The safety and efficacy outcomes were assessed 
comparatively with previously published data from SITS national and international registries.
Results: A total of 523 AIS patients were treated with IVT in 12 Greek centers participating in the 
SITS-ISTR during the study period (mean age 62.4 ± 12.7; 34.6% women; median baseline NIHSS 
score: 11 points; median OTT: 150 min). The rates of sICH were 1.4%, 2.3%, and 3.8% according 
to the SIST-MOST, ECASS II, and NINDS criteria respectively. The median reduction in NIHSS 
score at 2 and 24 h was 3 [interquartile range (IQR): 1–5] and 5 (IQR: 2–8) points respectively. The 
3-month FI, FFO and mortality were 66.5%, 55.6% and 7.9%. All safety and efficacy outcomes 
were comparable with available data from SITS-ISTR in other European countries.
Conclusions: Our study underscores the safety and efficacy of IVT for AIS in Greece. Additional 
action is necessary in order to increase the availability of IVT in the Greek population and to 
include more centers in the SITS-ISTR.
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(SITS-ISTR) have used the same international, 
multicenter, web-based database monitoring the 
safety and efficacy of intravenous tPA (tissue plas-
minogen activator) for AIS in different countries 
all over the world and in the European Union in 
particular.4,5 There are scarce data regarding out-
comes and complications of IVT for AIS in 
Greece.6,7 In view of the former considerations, 
we evaluated safety and efficacy outcomes of sys-
temic thrombolysis for AIS in Greece using the 
SITS-ISTR dataset that has been available in 
Greece during the past 15 years. These outcomes 
were also evaluated comparatively with previously 
published data from SITS registry in other 
European countries.
Methods
All AIS IVT patients in Greece treated within 4.5 
h from symptom onset recorded in the SITS-
ISTR between 25 December 2002 and 1 July 
2017 were evaluated. Demographics, risk factors, 
baseline stroke severity [defined using National 
Institutes of Health Stroke Scale (NIHSS)], and 
onset-to-treatment time (OTT) were recorded. 
Details regarding the definitions of baseline char-
acteristics in SITS registries have been previously 
published.4,5
Safety outcomes included symptomatic intracra-
nial hemorrhage (sICH) and 3-month mortality. 
sICH was defined using SITS-MOST, ECASS 
(European Cooperative Acute Stroke Study) II 
and NINDS (National Institute of Neurological 
Disorders) rtPA Stroke criteria. The NINDS def-
inition counts an ICH as symptomatic when any 
new hemorrhage on a brain computed tomogra-
phy (CT) scan within 7 days of treatment is asso-
ciated with any decline in neurologic status 
quantified as 1 or more points increase in the 
baseline NIHSS score.8 The ECASS II definition 
is consistent with any intracranial hemorrhage 
within 7 days of IVT leading to an increase in the 
NIHSS score of ⩾4 points compared with the 
baseline or to the lowest score in 7 days, or lead-
ing to death.9 The SITS-MOST defines sICH as 
a local or remote type II parenchymal hematoma 
within 22–36 h or sooner after treatment, associ-
ated with a worsening on the NIHSS score of at 
least 4 points from baseline assessment or from 
the lowest score from baseline to 24 h, or an ICH 
resulting in death.4
The efficacy outcomes assessed a reduction in the 
baseline NIHSS score at 2 and 24 h following tPA 
bolus, 3-month favorable functional outcome 
[FFO; defined as modified Rankin scale (mRS) 
scores of 0–1] and 3-month functional independ-
ence (FI; defined as mRS-scores of 0–2).4,10,11 
The safety and efficacy outcomes were evaluated 
comparatively with previously published data 
from the SITS registry in Italy,12 Austria,13 
Belgium14 and Poland,15 the SITS-EAST10 and 
the entire SITS-ISTR16 databases. The partici-
pating counties in SITS-EAST registry include 
Croatia, Czech Republic, Estonia, Greece, 
Hungary, Lithuania, Poland, Russia, Slovakia, 
Slovenia and Turkey, representing approximately 
30% of the population of the SITS registry.10
The present study is a retrospective analysis of 
registered Greek AIS patients in the SITS-ISTR 
dataset. SITS-Greece is embedded within the 
SITS-ISTR, which was originally approved by the 
Ethics Committee of Karolinska Institutet, 
Stockholm.5 Further approval from institutional 
Ethics Committee was obtained in institutions 
that required this, while other institutions 
approved the register for conduct as an anonymized 
audit. Informed consent was obtained from 
patients or their relatives according to the existing 
regulations in each participating institution.
Statistical analysis
Continuous variables are presented as mean val-
ues with standard deviation (SD) or median val-
ues with the corresponding interquartile range 
(IQR) as appropriate. To compare the rates of 
safety and efficacy outcomes between the differ-
ent patient cohorts, we calculated the percent-
ages, with corresponding 95% confidence 
intervals (95% CI). We also presented graphically 
the serial assessments of median NIHSS scores, 
with their corresponding IQRs, reported in both 
the SITS-ISTR Greek and SITS-EAST cohorts. 
Finally, we calculated the differences in serial 
assessments of the NIHSS scores of AIS patients 
reported in the SITS-ISTR Greek cohort at 2 h 
(dNIHSS at 2 h = baseline NIHSS − NIHSS at 
2 h) and 24 h (dNIHSS at 24 h = baseline NIHSS 
− NIHSS at 24 h) following tPA bolus. All statis-
tical analysis were performed with the Stata 
Statistical Software version 13 for Windows 
(StataCorp LP, College Station, TX, USA).
Results
A total of 523 AIS patients were treated with 
IVT in 12 Greek centers participating in the 
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SITS-ISTR registry during the study period 
(mean age 62.4 ± 12.7; 34.6% women; median 
baseline NIHSS score: 11 points, IQR: 7–17). As 
evident from Figure 1 the aforementioned centers 
are dispersed across almost all of the Greek terri-
tory, while three of them are located in Athens – 
the capital city of Greece inhabited by nearly the 
one third of the total Greek population. Baseline 
characteristics and outcomes of the study popula-
tion are presented in Table 1. About one quarter 
of the study population reported pretreatment 
with antiplatelet and lipid-lowering, while 
19.3% were diabetic. Onset-to-door, door-to- 
needle and OTT times were 70 (IQR: 45–110), 
67 (IQR: 50–92) and 150 (IQR: 120–180) min 
respectively (Table 1).
The rates of sICH were 1.4% (95% CI: 0.3–4.2%), 
2.3% (95% CI: 0.8–5.5%), and 3.8% (95% CI: 
1.5–6.7%) according to the SITS-MOST, ECASS 
II, and NINDS criteria respectively (Table 1). The 
median reduction in NIHSS score at 2 and 24 h 
was 3 (IQR: 1–5) and 5 (IQR: 2–8) points respec-
tively. Figure 2 displays graphically the NIHSS 
score evolution in the Greek and the SITS-EAST 
patient cohorts. Early clinical improvement of the 
neurological deficits attributed to AIS was compa-
rable between the two cohorts. More specifically, in 
the Greek cohort, the NIHSS score declined from 
a baseline value of 11 (IQR: 7–17) to 7 (IQR: 3–14) 
and to 4 points (IQR: 1–12) at 2 and 24 h following 
tPA bolus. Similarly, in the SITS-EAST cohort, 
the NIHSS score declined from a baseline value of 
11 (IQR: 7–16) to 8 (IQR: 4–14) and to 6 points 
(IQR: 2–13) at 2 and 24 h following tPA bolus.
The 3-month FI, FFO and mortality were 66.5% 
(95% CI: 62.0–70.7%), 55.6% (95% CI: 51.1–
60.1%) and 7.9% (95% CI: 5.8–10.7%). All safety 
and efficacy outcomes of IVT in Greece were com-
parable with available data from SITS-ISTR regis-
try in other European countries (Table 2 and 
Figure 1. Map of Greece indicating the location of centers participating actively in the Safe Implementation 
of Thrombolysis in Stroke registry and providing treatment with intravenous thrombolysis in acute ischemic 
stroke patients.
(1): Department of Neurology, University Hospital of Alexandroupolis, Alexandroupolis; (2): Department of Neurology, 
Papageorgiou Hospital, Thessaloniki; (3): Second Department of Neurology, AHEPA University Hospital, Thessaloniki; (4): 
Department of Neurology, University Hospital of Ioannina, Ioannina; (5): Department of Neurology, University Hospital of 
Larissa, Larissa; (6): Intensive Care Unit, General Hospital of Larissa, Larissa; (7): Second Department of Neurology, Attikon 
University Hospital, Athens, (8): Department of Neurology, Evangelismos Hospital, Athens; (9): Department of Neurology, 
Athens General Hospital G. Gennimatas, Athens; (10): Stroke Unit, Metropolitan Hospital, Piraeus; (11): Department of 
Neurology, University Hospital of Patras, Patras; (12): Department of Neurology, University Hospital of Heraklion, Heraklion.
Therapeutic Advances in Neurological Disorders 11
4 journals.sagepub.com/home/tan
Table 1. Baseline characteristics and outcomes of acute stroke patients treated with intravenous thrombolysis 
according to the Safe Implementation of Treatments in Stroke protocol in Greece.
Variable n = 523
Baseline characteristics  
Age (mean ± SD), years 62.4 ± 12.7
Females (%) 34.6%
Admission NIHSS (median, IQR) 11 (7–17)
Hypertension (%) 60.0%
Diabetes (%) 19.3%
Hyperlipidemia (%) 36.6%
Current smoking (%) 33.1%
Previous stroke (%) 11.4%
Atrial fibrillation (%) 15.3%
Congestive heart failure (%) 3.3%
Antiplatelet pretreatment (%) 27.8%
Antidiabetic pretreatment (%) 12.5%
Antihypertensive pretreatment (%) 52.6%
Statin pretreatment (%) 24.9%
Admission SBP baseline (mean ± SD), mmHg 149 ± 24
Admission DBP (mean ± SD), mmHg 83 ± 13
Admission serum glucose (median, IQR), mg/dl 115 (100–144)
Baseline total cholesterol (mean ± SD), mg/dl 187 ± 54
Early ischemic changes in baseline CT scan (%) 8.3%
Disability prior to index event (%)* 2.5%
Acute ischemic stroke subtype (%) Large artery atherosclerosis: 51.4%
Cardioembolism: 21.2%
Small vessel disease: 9.3%
Cryptogenic: 9.9%
Other unusual causes: 2.9%
Not available: 5.3%
Times from stroke onset to treatment  
Onset-to-door time (min, median, IQR) 70 (45–110)
Door-to-imaging time (min, median, IQR) 30 (20–45)
G Tsivgoulis, O Kargiotis et al. 
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Variable n = 523
Door-to-needle time (min, median, IQR) 67 (50–92)
Onset-to-treatment time (min, median, IQR) 150 (120–180)
Outcomes  
Any ICH (%, 95% CI) 58/503 (11.5%, 9.0–14.6%)
sICH – SITS-MOST (%, 95% CI) 3/214 (1.4%, 0.3–4.2%)
sICH – ECASS (%, 95% CI) 5/214 (2.3%, 0.8–5.5%)
sICH – NINDS (%, 95% CI) 7/214 (3.8%, 1.5–6.7%)
dNIHSS at 2 h 3 (1–5)
dNIHSS at 24 h 5 (2–8)
mRS at 3-months (median, IQR) 1 (0–4)**
FFO (mRS: 0–1) at 3-months (%, 95% CI) 262/471 (55.6%, 51.1–60.1%)**
FI (mRS: 0–2) at 3-months (%, 95% CI) 313/471 (66.5%, 62.0–70.7%)**
Mortality at 3-months (%, 95% CI) 37/471 (7.9%, 5.8–10.7%)**
*mRS score prior to stroke onset >1.
**last observation carried forward; follow-up was available in 471 patients.
CI, confidence interval; CT, computed tomography; DBP, diastolic blood pressure; dNIHSS, difference in NIHSS score 
from baseline; ECASS, European Cooperative Acute Stroke Study; FFO, favorable functional outcome; FI, functional 
independence; ICH, intracerebral hemorrhage; IQR, interquartile range; mRS, modified Rankin scale score; NIHSS, 
National Institutes of Health Stroke Scale; NINDS, National Institute of Neurological Disorders and Stroke; SBP, systolic 
blood pressure; SD, standard deviation; sICH, symptomatic ICH; SITS-MOST, Safe Implementation of Treatments in 
Stroke Monitoring Study.
Table 1. (Continued)
Figure 2. Serial assessments of National Institutes of Health Stroke Scale scores at baseline, 2 and 24 h 
following tPA bolus in acute ischemic stroke patients reported in the Safe Implementation of Treatments in 
Stroke Greek (blue line) and EAST registry (red line).
tPA, tissue plasminogen activator.
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Figure 3). More specifically, there was substantial 
overlap in the 95% CI of reported outcomes 
between the Greek and other available SITS regis-
tries (Table 2), while the highest rate of FI at 3 
months was documented in the Greek cohort 
(Figure 3).
Discussion
Our study underlines the safety and efficacy of 
IVT for AIS in Greece. To the best of our knowl-
edge, this is the largest series of AIS patients 
treated with IVT in Greece over a 15-year period. 
It should be noted that registration of IVT patient 
data into SITS-ISTR is not mandatory in Greece, 
yet is highly recommended. Nevertheless, there 
are some institutions that do not include AIS 
patients treated with IVT in the SITS registry. 
Since there is no Greek national thrombolysis 
registry, SITS is the only registry where safety 
and outcomes after IVT can be assessed in the 
vast majority of tertiary care stroke centers from 
all over Greece. Therefore, we consider SITS-
ISTR data as fully representative of acute stroke 
care in terms of systemic reperfusion in our 
country.
Another important aspect deriving from the pre-
sent analysis is that the median OTT time (150 
min) is similar to that of other national and inter-
national dataset of SITS registries. OTT is an 
established measure reflecting the quality of an 
acute stroke system of care.3,17 Despite the signifi-
cant impact of the financial crisis on the national 
health system, depriving Greek hospitals of both 
human as well as material resources and given the 
lack of organization of stroke unit care system at a 
national level,18 the achieved OTT in the present 
study indicates the tremendous efforts of the 
healthcare personnel to maintain the quality of 
stroke care in Greece. On the other hand, the 
compelling need for improvement of our median 
door-to-needle time of 67 min needs to be 
acknowledged. The future efforts of SITS investi-
gators in Greece will focus on implementation of 
the Helsinki Stroke Thrombolysis model19 in 
order to reduce delays in door-to-needle time by 
at least 20 min. Notably, the transferability of this 
model in stroke systems of care outside Finland 
has been shown to be feasible and effective.20
The safety and efficacy outcomes in our cohort 
were comparable with those of larger datasets of 
SITS registries.4,10,12–16 Compared with other 
cohorts, in the Greek cohort there was a trend 
towards a higher rates of 90-day FI (mRS 0–2) or 
FFO (mRS 0–1) and lower rates of mortality and 
sICH, particularly according to NINDS and 
ECASS definitions. This finding could probably 
be attributed to the younger age and lower median 
NIHSS scores at baseline of patients included in 
the Greek cohort (Table 2). The possibility of 
selection bias should also be taken into considera-
tion due to the presentation of data only from 
centers actively participating in the SITS registry. 
However, it should also be noted that the rates of 
sICH, 3-month mortality and 3-month FFO that 
we documented in the present study were very 
close to those reported by two individual patient 
data meta-analyses pooling data from all available 
randomized-controlled clinical trials of IVT for 
AIS.21,22
To our knowledge this is the first and only study 
so far providing data on the outcomes of IVT-
treated AIS patients in Greece. Despite these 
encouraging results, there are still several actions 
to be undertaken in order to further increase tPA 
availability in Greece. There are numerous organ-
izational obstacles that have to be overcome, as 
well as innovations that have to be adopted. For 
instance, the availability of IVT has to be 
expanded beyond the main large cities to smaller 
cities, islands and rural areas by developing 
stroke-oriented and efficient transfer protocols, 
by emergency medical services and telestroke 
facilities focused on efficient recognition and fast 
triage of eligible candidates for IVT.23,24 Finally, a 
media campaign, aimed to enhance public aware-
ness on stroke symptoms and the beneficial effects 
of timely reperfusion,25,26 would definitely 
increase acute reperfusion treatment rates in 
Greece.
Certain limitations of the present study need to 
be addressed. First, we should acknowledge that 
the number of patients included in our cohort, 
although numerically comparable to the previ-
ously published nationwide studies (Table 2), is 
relatively small given the extended time period of 
15 years. Apart from the low number of included 
patients, it should be noted that potential imbal-
ances in thrombolysis rates and heterogeneity in 
stroke care delivery between participating centers 
might also be present. Second, we did not per-
form formal statistical comparisons of baseline 
characteristics and outcomes between the Greek 
and the other SITS registry cohorts, since the 
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Figure 3. Bar charts with corresponding upper 95% confidence intervals on the rates of (a) symptomatic 
intracerebral hemorrhage, (b) 3-month mortality and (c) 3-month functional independence reported in available 
national and international stroke registries of acute stroke patients treated with intravenous thrombolysis.
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individual patient data of the other national and 
international registries were not available. Third, 
as we have already mentioned the SITS-ISTR 
registry does not capture all institutions in Greece 
treating AIS patients with IVT. Moreover, it 
should be noted that there is a potential risk of 
selection bias given that data for all potentially eli-
gible IVT patients are not provided from partici-
pating centers. Fourth, the outcomes in SITS 
registry are self-reported and this may introduce 
numerous sources of bias. Finally, given the lim-
ited availability of endovascular reperfusion ther-
apies in Greece,27 we did not report separate 
outcomes in patients treated with bridging ther-
apy (IVT followed by mechanical thrombectomy) 
in the present cohort.
In conclusion, our study underscores the tolera-
bility and efficacy of IVT for AIS in Greece. The 
present findings may serve as a roadmap for the 
improvement of organization of acute stroke care 
at a national level. Additional action is necessary 
in order to increase the availability of systemic 
thrombolysis in the Greek population, to shorten 
door-to-needle times and to include more centers 
in the SITS-ISTR registry.
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